Literature DB >> 23995619

Analytical characterization of a monoclonal antibody therapeutic reveals a three-light chain species that is efficiently removed using hydrophobic interaction chromatography.

Rachel B Wollacott1, Paul L Casaz1, Trevor J Morin2, H Lily Zhu1, Roger S Anderson1, Gregory J Babcock2, John Que1, William D Thomas1, Sadettin S Ozturk1.   

Abstract

Size exclusion high performance liquid chromatography analysis of a human monoclonal antibody (mAb) showed the presence of a new species that eluted with a retention time between the dimeric and monomeric species of the antibody. Extensive characterization of this species, referred to as "shoulder," indicated that it was a mAb containing an extra light chain and had a molecular weight of approximately 175 kDa. The extra light chain was found to be non-covalently associated with the Fab portion of the protein. The relative amount of shoulder (typically 1-3% of the total mAb present) varied with the Chinese hamster ovary cell line producing the mAb and was not influenced by the growth conditions. Our three-step mAb purification platform using protein A, anion exchange, and cation exchange process steps was successful at removing dimer and higher and lower molecular weight species, but not the shoulder impurity. It was found that hydrophobic interaction chromatography could be used in place of cation exchange to exploit the subtle differences in hydrophobicity between monomer and shoulder. We developed an antibody polishing process using Butyl Sepharose HP resin that is capable of removing the majority of high and low molecular weight impurities yielding 99% pure mAb monomer, virtually devoid of the shoulder species, with a step recovery of about 80%.

Entities:  

Keywords:  antibody size variant; design of experiments; hydrophobic interaction chromatography; monoclonal antibody; size exclusion chromatography; third light chain

Mesh:

Substances:

Year:  2013        PMID: 23995619      PMCID: PMC3896606          DOI: 10.4161/mabs.26192

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  14 in total

Review 1.  Structure-immunogenicity relationships of therapeutic proteins.

Authors:  Suzanne Hermeling; Daan J A Crommelin; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

Review 2.  A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

Authors:  Robert M Anthony; Jeffrey V Ravetch
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

3.  High-throughput process development for recombinant protein purification.

Authors:  Kaushal Rege; Mike Pepsin; Brandy Falcon; Landon Steele; Meng Heng
Journal:  Biotechnol Bioeng       Date:  2006-03-05       Impact factor: 4.530

Review 4.  Effects of protein aggregates: an immunologic perspective.

Authors:  Amy S Rosenberg
Journal:  AAPS J       Date:  2006-08-04       Impact factor: 4.009

5.  Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography.

Authors:  Jian Yang; Sean Wang; Jennifer Liu; Anil Raghani
Journal:  J Chromatogr A       Date:  2007-02-15       Impact factor: 4.759

Review 6.  High-throughput process development for biopharmaceutical drug substances.

Authors:  Rahul Bhambure; Kaushal Kumar; Anurag S Rathore
Journal:  Trends Biotechnol       Date:  2011-01-20       Impact factor: 19.536

7.  Effect of temperature, pH, dissolved oxygen, and hydrolysate on the formation of triple light chain antibodies in cell culture.

Authors:  Natalia Gomez; Jun Ouyang; Mary D H Nguyen; Abigail R Vinson; Andy A Lin; Inn H Yuk
Journal:  Biotechnol Prog       Date:  2010 Sep-Oct

8.  Characterization of monoclonal antibody size variants containing extra light chains.

Authors:  Connie Lu; Dandan Liu; Hongbin Liu; Paul Motchnik
Journal:  MAbs       Date:  2012-12-19       Impact factor: 5.857

9.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Authors:  Christine H Chung; Beloo Mirakhur; Emily Chan; Quynh-Thu Le; Jordan Berlin; Michael Morse; Barbara A Murphy; Shama M Satinover; Jacob Hosen; David Mauro; Robbert J Slebos; Qinwei Zhou; Diane Gold; Tina Hatley; Daniel J Hicklin; Thomas A E Platts-Mills
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

Review 10.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs.

Authors:  T Shantha Raju
Journal:  Curr Opin Immunol       Date:  2008-07-17       Impact factor: 7.486

View more
  3 in total

1.  Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.

Authors:  Rabah Gahoual; Michaël Biacchi; Johana Chicher; Lauriane Kuhn; Philippe Hammann; Alain Beck; Emmanuelle Leize-Wagner; Yannis N François
Journal:  MAbs       Date:  2014       Impact factor: 5.857

2.  Isolation and characterization of a monoclonal antibody containing an extra heavy-light chain Fab arm.

Authors:  Dan Boyd; Arpa Ebrahimi; Sarah Ronan; Brian Mickus; Matthew Schenauer; Jenny Wang; Darren Brown; Alexandre Ambrogelly
Journal:  MAbs       Date:  2018-03-20       Impact factor: 5.857

3.  Identification and characterization of an IgG sequence variant with an 11 kDa heavy chain C-terminal extension using a combination of mass spectrometry and high-throughput sequencing analysis.

Authors:  Claire Harris; Weichen Xu; Luigi Grassi; Chunlei Wang; Abigail Markle; Colin Hardman; Richard Stevens; Guillermo Miro-Quesada; Diane Hatton; Jihong Wang
Journal:  MAbs       Date:  2019-10-01       Impact factor: 5.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.